Back to Agenda
US Executive Orders: Impact on Precision Medicine and Diagnostic Development
Session Chair(s)
Courtney Granville, PHD, MPH
United States
As of April 2, 2025, President Trump signed 103 Executive Orders in 2025 (EO 14147 to EO 14249) and sweeping government actions have led to widespread change in the health and biomedical research industries. Impacts on precision the effects of many of the Orders are largely unknown and tied up in legislative process. This has created considerable uncertainty for biomedical research and subsequent development of precision medicines and diagnostics. In this session we will review the 2025 Executive Orders, the court decision striking down the LDT Final Rule, and certain organizational changes at FDA that impact precision medicine and research and will delve deeper into the global impacts that are expected as a result.
Learning Objective : List 2025 Executive Orders affecting personalized medicine and innovation in product and diagnostics development; Summarize impacts of 2025 Executive Orders on health innovation, research, regulations including the LDT final rule and patients; Discuss potential implications of current changes in the environment on global R&D.
Speaker(s)
Panelist
Megan Doyle, JD, MPH
Eli Lilly and Company, United States
Associate Vice President, Assistant General Counsel - Diagnostics
Panelist
Lia Ridout
-, United States
Patient Advocate
Panelist
Carly McWilliams, MBA
Roche Diagnostics, United States
Head of Regulatory Policy
Panelist
Nathan Brown, JD
Akin Gump Strauss Hauer & Feld LLP, United States
Partner
Have an account?